American Capital Advisory’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.3K Buy
270
+1
+0.4% +$83 0.01% 295
2026
Q2
$18.1K Buy
269
+2
+0.7% +$133 0.01% 310
2026
Q1
$16.8K Buy
267
+4
+2% +$279 0.01% 305
2025
Q4
$17.5K Buy
263
+4
+2% +$259 0.01% 292
2025
Q3
$17.4K Sell
259
-1
-0.4% -$79 0.01% 277
2025
Q2
$22.7K Buy
260
+10
+4% +$784 0.01% 254
2025
Q1
$17.1K Hold
250
– – 0.01% 272
2024
Q4
$19.4K Buy
+250
New +$18.5K 0.01% 253
2024
Q3
– Sell
-190
Closed -$23.6K – 489
2024
Q2
$23.6K Buy
+190
New +$24K 0.02% 207
2024
Q1
– Sell
-190
Closed -$23.6K – 476
2023
Q4
$23.6K Buy
+190
New +$19.4K 0.02% 207

Other funds holding DXCM

American Capital Advisory's DXCM Position: Q3 2026 in Review

American Capital Advisory increased its DexCom (DXCM) stake by 0.37% in Q3 2026, buying an estimated $83 and bringing the position to 270 shares worth $23.3K. The position accounts for 0.01% of the portfolio, ranked #295.

American Capital Advisory first reported a position in DXCM in Q4 2023 and has held it in 10 quarters since. The position peaked at $23.6K in Q2 2024. 1,056 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • American Capital Advisory held 270 shares of DexCom worth $23.3K as of Q3 2026.
  • American Capital Advisory bought 1 DexCom share in Q3 2026, an estimated $83.
  • DexCom made up 0.01% of American Capital Advisory's portfolio in Q3 2026, its #295 holding.
  • American Capital Advisory first reported a position in DexCom in Q4 2023 and has held it in 10 quarters since.
  • American Capital Advisory's DexCom position peaked at $23.6K in Q2 2024.
  • 1,056 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on American Capital Advisory's 13F filing for Q3 2026, filed 28 Oct 2026.